8-K: Telesis Bio Reports Record BioXp Kit Sales and Reduced Operating Expenses in 2023

Telesis Bio announced its fourth quarter and full year 2023 financial results, highlighting record BioXp kit sales, improved gross margins, and significant reductions in operating expenses.

Summary

• Telesis Bio reported its financial results for the fourth quarter and full year of 2023.
• BioXp kit revenue reached a record high of over $1.0 million in the fourth quarter, a 59.6% increase from the previous quarter and a 25.9% increase compared to the same quarter in 2022.
• Full year BioXp kit sales increased by 10% compared to the prior year.
• Total consolidated revenue for 2023 was $27.5 million, slightly up from $27.4 million in 2022.
• Excluding BioXp instrument sales and discontinued BioFoundry Services, total revenue was $20.9 million, a 12.4% increase from $18.6 million in the prior year.
• Collaboration revenue increased by 30.7% to $8.7 million, up from $6.7 million in the previous year.
• Operating expenses for the full year were reduced by 16.1% to $52.1 million, excluding a non-cash goodwill impairment.
• The company completed its program to insource oligo supply, now capable of supplying at least 70% of its needs.
• Gross margin for the full year increased to 61.6% from 56.8% in the prior year.
• The company recorded a goodwill impairment charge of $11.4 million in the fourth quarter.
• Net loss for the year was $49.0 million, compared to $48.5 million in the prior year.
• Cash, cash equivalents, restricted cash, and investments totaled $19.3 million as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents mixed results with positive highlights such as record BioXp kit sales and reduced operating expenses, but also negative aspects like a significant net loss, a goodwill impairment charge, and a decrease in cash reserves. The lack of forward guidance also adds uncertainty.

Positives

• Record BioXp kit sales indicate strong product adoption.
• Significant growth in mRNA workflows demonstrates the effectiveness of their technology.
• Increased collaboration revenue shows successful partnerships and technology milestones.
• Reduced operating expenses reflect successful cost-cutting initiatives.
• Improved gross margin indicates better profitability per sale.
• Insourcing oligo supply and instrument manufacturing is expected to further improve margins and product quality.
• The company has a strategic research collaboration with Pfizer.

Negatives

• Total revenue for the fourth quarter was down compared to the same period in the prior year due to capital spending weakness.
• The company recorded a significant goodwill impairment charge of $11.4 million.
• Net loss for the year was $49.0 million, although this was similar to the prior year.
• The company's cash position decreased significantly from $43.7 million to $19.3 million year-over-year.

Risks

• The company is operating in a challenging macro environment.
• Continued capital spending weakness in the industry could impact future revenue.
• The company's cash position has decreased significantly.
• The company is not issuing additional forward-looking guidance at this time.
• The company's future performance is subject to risks and uncertainties described in their annual report.

Future Outlook

The company will not be issuing additional forward-looking guidance at this time, but anticipates continued growth in the use of RNA in drug discovery workflows and intends to prioritize development of its BioXp and SOLA platforms.

Management Comments

• Todd R. Nelson, CEO, stated he was pleased with the company's operating execution in a challenging macro environment.
• Todd R. Nelson, CEO, highlighted record BioXp kit sales and expanding gross margin due to cost-cutting initiatives.
• Todd R. Nelson, CEO, believes their mRNA synthesis kits are game-changing and provide customers with control over their screening and discovery.

Industry Context

The announcement reflects the growing industry-wide acceptance of mRNA technology and the increasing demand for rapid and flexible synthesis solutions in drug discovery and development. The company's focus on mRNA and DNA synthesis aligns with current trends in the biotechnology sector.

Comparison to Industry Standards

• Telesis Bio's 10% increase in BioXp kit sales for the full year is a positive sign, but it is important to compare this to the growth rates of other companies in the synthetic biology and genomics space, such as Twist Bioscience and Ginkgo Bioworks.
• The 30.7% increase in collaboration revenue is a strong indicator of the company's ability to form partnerships and generate revenue from its technology, which is comparable to other companies with similar business models.
• The reduction in operating expenses by 16.1% is a significant achievement, but it is important to assess whether this reduction has impacted the company's ability to invest in research and development compared to its peers.
• The gross margin of 61.6% is a positive development, but it is important to compare this to the gross margins of other companies in the industry to determine if it is competitive.
• The company's net loss of $49.0 million is a concern, and it is important to compare this to the net losses of other companies in the industry to determine if it is within the expected range for a company at this stage of development.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decrease in cash reserves.
• Employees may be impacted by the restructuring and headcount reduction.
• Customers may benefit from the company's focus on improving its BioXp and SOLA platforms.
• Suppliers may be impacted by the company's insourcing of oligo supply and instrument manufacturing.
• Creditors may be concerned about the company's financial performance and cash position.

Next Steps

• The company intends to prioritize the development of its BioXp and SOLA platforms.
• The company expects favorable reductions to operating expenses in 2024 due to cost reduction activities completed in 2023.
• The company expects improved gross margin and product quality in 2024 due to insourcing of oligo supply and instrument manufacturing.

Key Dates

Keywords

BioXp, mRNA, DNA, RNA, synthetic biology, oligonucleotide, biopharma, genomics, cell therapy, gene therapy, vaccine development, drug discovery